Face-to-face Versus Online Hypnotherapy for the Treatment of Irritable Bowel Syndrome

NCT ID: NCT03899779

Last Updated: 2025-07-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

282 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-08

Study Completion Date

2025-06-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psychological therapies are effective in reducing irritable bowel syndrome (IBS) symptom severity and increasing quality of life and are recommended for the management of IBS by guidelines. Evidence appears strongest for the efficacy of hypnotherapy as psychological treatment. However, therapist-led interventions are time consuming and relatively costly. Approaches based on e-health are cost saving and appear more attractive to patients as no visits to a therapist are necessary. Therefore, the investigators plan to conduct a multicentre randomised controlled trial to examine whether the effectiveness of online hypnotherapy is non-inferior compared to individual face-to-face hypnotherapy delivered by a therapist, according to current FDA guidelines. Online psychoeducation will be used as control condition. In addition, the investigators hypothesize that treatment with online hypnotherapy is a more cost-effective therapy than face-to-face hypnotherapy in IBS patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Face-to-face hypnotherapy

12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)

Group Type ACTIVE_COMPARATOR

Face-to-face hypnotherapy

Intervention Type OTHER

12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)

Online hypnotherapy

12 weeks treatment with online hypnotherapy

Group Type EXPERIMENTAL

Online hypnotherapy

Intervention Type OTHER

12 weeks treatment with online hypnotherapy

Online psychoeducation

12 weeks treatment with online psychoeducation

Group Type ACTIVE_COMPARATOR

Online psychoeducation

Intervention Type OTHER

12 weeks treatment with online psychoeducation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Face-to-face hypnotherapy

12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)

Intervention Type OTHER

Online hypnotherapy

12 weeks treatment with online hypnotherapy

Intervention Type OTHER

Online psychoeducation

12 weeks treatment with online psychoeducation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 16-75 years
* A diagnosis of IBS according to the Rome IV criteria
* In the presence of alarm symptoms, such as rectal blood loss, weight loss, anemia, first onset of symptoms above 50 years of age, patients will be first referred for further investigation by their treating physician to exclude organic disorders, conform current Dutch guidelines for IBS.
* Women in fertile age must use contraception or be postmenopausal for at least two years.

Exclusion Criteria

* Insufficient command of the Dutch language
* No access to internet
* Evidence of current anxiety and/or depression disorder as defined by a score ≥10 on the GAD-7 and/or PHQ-9 questionnaire. In this case it is conceivable that the IBS symptoms are strongly related to psychopathology for which different treatment might be more appropriate.
* History of ulcerative colitis, Crohn's disease, coeliac disease or significant liver disease
* Major surgery to the lower gastrointestinal tract, such as partial or total colectomy, small bowel resection or partial or total gastrectomy
* Past or present radiotherapy to the abdomen
* Current pregnancy or lactation
* Using of psychoactive medication in case there's no stable dose for at least 3 months prior to inclusion
* Use of over-the-counter or prescription antidiarrheals, analgesics and laxatives (only be allowed as specific rescue medication)
* Hypnotherapy treatment received in the last 3 months prior to inclusion
* Using more than 20 units of alcohol per week
* Using drugs of abuse
Minimum Eligible Age

16 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

Sponsor Role collaborator

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Keszthelyi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gelderse Vallei

Ede, Gelderland, Netherlands

Site Status

Maastricht University Medical Center

Maastricht, Limburg, Netherlands

Site Status

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, North Brabant, Netherlands

Site Status

Bernhoven

Uden, North Brabant, Netherlands

Site Status

Medisch Centrum Leeuwarden

Leeuwarden, Provincie Friesland, Netherlands

Site Status

Martini Ziekenhuis

Groningen, Provincie Groningen, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

852001924

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

METC18-037

Identifier Type: OTHER

Identifier Source: secondary_id

NL67607.068.18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Psychological and Dietary Treatment in IBS
NCT04770883 NOT_YET_RECRUITING NA